中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2011年
10期
1305-1308
,共4页
段波峰%郑维%唐梅徕%范培芝%张超杰%谢靖%李洋%雷珊珊%顾晓文%何杰
段波峰%鄭維%唐梅徠%範培芝%張超傑%謝靖%李洋%雷珊珊%顧曉文%何傑
단파봉%정유%당매래%범배지%장초걸%사정%리양%뢰산산%고효문%하걸
乳腺肿瘤/代谢%受体,CXCR3/代谢%趋化因子CXCL10/代谢
乳腺腫瘤/代謝%受體,CXCR3/代謝%趨化因子CXCL10/代謝
유선종류/대사%수체,CXCR3/대사%추화인자CXCL10/대사
Breast neoplasms/ME%Receptors,CXCR3/ME%Chemokine CXCL10/ME
目的 探讨趋化因子受体3( CXCR3)及趋化因子配体10(CXCL10)在乳腺癌中的表达及临床意义.方法 采用免疫组织化学SP法及二步法对60例乳腺癌组织、20例乳腺纤维瘤组织及20例乳腺腺病组织分别进行CXCR3、CXCL10检测.结果 乳腺癌中CXCR3( 40/60,66.7％)、CXCL10( 45/60,75％)的表达高于乳腺腺病[CXCR3( 8/20,40％)x2=4.44,P=0.035；CXCL10( 10/20,50％) x2=4.36,P=0.037)],乳腺癌中CXCR3的表达与有无腋窝淋巴结转移、临床分期、HER-2的表达有关(x2=4.15,p =0.042;x2 =7.74,P=0.021；x2 =4.27,P=0.039),且CXCR3的表达强度与腋窝淋巴结转移数及临床分期目呈正相关(rs=0.375,P=0.003；rs=0.451,P=0.000).结论 CXCR3可能与乳腺癌的进展及早期转移有关,CXCR3可能作为乳腺癌的一个预后指标.
目的 探討趨化因子受體3( CXCR3)及趨化因子配體10(CXCL10)在乳腺癌中的錶達及臨床意義.方法 採用免疫組織化學SP法及二步法對60例乳腺癌組織、20例乳腺纖維瘤組織及20例乳腺腺病組織分彆進行CXCR3、CXCL10檢測.結果 乳腺癌中CXCR3( 40/60,66.7％)、CXCL10( 45/60,75％)的錶達高于乳腺腺病[CXCR3( 8/20,40％)x2=4.44,P=0.035；CXCL10( 10/20,50％) x2=4.36,P=0.037)],乳腺癌中CXCR3的錶達與有無腋窩淋巴結轉移、臨床分期、HER-2的錶達有關(x2=4.15,p =0.042;x2 =7.74,P=0.021；x2 =4.27,P=0.039),且CXCR3的錶達彊度與腋窩淋巴結轉移數及臨床分期目呈正相關(rs=0.375,P=0.003；rs=0.451,P=0.000).結論 CXCR3可能與乳腺癌的進展及早期轉移有關,CXCR3可能作為乳腺癌的一箇預後指標.
목적 탐토추화인자수체3( CXCR3)급추화인자배체10(CXCL10)재유선암중적표체급림상의의.방법 채용면역조직화학SP법급이보법대60례유선암조직、20례유선섬유류조직급20례유선선병조직분별진행CXCR3、CXCL10검측.결과 유선암중CXCR3( 40/60,66.7％)、CXCL10( 45/60,75％)적표체고우유선선병[CXCR3( 8/20,40％)x2=4.44,P=0.035；CXCL10( 10/20,50％) x2=4.36,P=0.037)],유선암중CXCR3적표체여유무액와림파결전이、림상분기、HER-2적표체유관(x2=4.15,p =0.042;x2 =7.74,P=0.021；x2 =4.27,P=0.039),차CXCR3적표체강도여액와림파결전이수급림상분기목정정상관(rs=0.375,P=0.003；rs=0.451,P=0.000).결론 CXCR3가능여유선암적진전급조기전이유관,CXCR3가능작위유선암적일개예후지표.
Objective To investigate the expression and clinical significance of CXCR3/CXCL10in human cancer.Methods CXCR3 and CXCL10 were detected in 60 paraffinic tissues of patients with primary breast cancer,20 of mammary fibroma and 20 of mastopathy by immunohistochemistry S-P method and two stage method.Results The expression of CXCR3 (40/60,66.7％ ) and CXCL10 (45/60,75％)in breast cancer was higher than that in mastopathy [CXCR3(8/20,40％ )x2 =4.44,P =0.035 ;CXCL10( 10/20,50％ )x2 =4.36,P =0.037)].The expression of CXCR3 was related to status of axillary lymph node metastasis,clinical stage and the expression of HER-2 (x2 =4.15,P =0.042; x2 =7.74,P =0.021 ;x2 =4.27,P =0.039).The expression of CXCR3 had positive relationship to the number axillary lymph node metastasis( rs =0.375,P =0.003 ),clinical stage ( rs =0.451,P =0.000).Conclusions CXCR3 may be related to the progression and metastasis of breast cancer,and it may be used as a marker of breast cancer prognosis.
